Department of Medicine at the Doherty Institute, The University of Melbourne, Melbourne, Australia.
Indian J Med Res. 2017 Sep;146(3):328-333. doi: 10.4103/ijmr.IJMR_1304_17.
Pregnant women are especially susceptible to malaria infection. Without existing immunity, severe malaria can develop requiring emergency treatment, and pregnancy loss is common. In semi-immune women, consequences of malaria for the mother include anaemia while stillbirth, premature delivery and foetal growth restriction affect the developing foetus. Preventive measures include insecticide-treated nets and (in some African settings) intermittent preventive treatment. Prompt management of maternal infection is key, using parenteral artemisinins for severe malaria, and artemisinin combination treatments (ACTs) in the second and third trimesters of pregnancy. ACTs may soon also be recommended as an alternative to quinine as a treatment in the first trimester of pregnancy. Monitoring the safety of antimalarials and understanding their pharmacokinetics is particularly important in pregnancy with the altered maternal physiology and the risks to the developing foetus. As increasing numbers of countries embrace malaria elimination as a goal, the special needs of the vulnerable group of pregnant women and their infants should not be overlooked.
孕妇尤其容易感染疟疾。由于没有现有的免疫力,严重的疟疾可能会发展为需要紧急治疗,妊娠丢失也很常见。在半免疫的女性中,疟疾对母亲的后果包括贫血、死产、早产和胎儿生长受限,影响胎儿发育。预防措施包括使用经杀虫剂处理的蚊帐和(在一些非洲环境中)间歇性预防治疗。及时治疗母亲的感染是关键,对严重疟疾使用注射用青蒿素,在妊娠第二和第三 trimester 使用青蒿素联合治疗(ACT)。ACT 可能很快也被推荐作为治疗妊娠早期的奎宁的替代药物。监测抗疟药物的安全性并了解其药代动力学在妊娠期间尤为重要,因为母体生理学发生变化,而且会对发育中的胎儿造成风险。随着越来越多的国家将消除疟疾作为目标,孕妇及其婴儿这一弱势群体的特殊需求不应被忽视。